Search
Search
{{#data.error.root_cause}}
{{/data.error}}
{{^data.error}}
{{#texts.summary}}
[{{{type}}}] {{{reason}}}
{{/data.error.root_cause}}{{texts.summary}} {{#options.result.rssIcon}} RSS {{/options.result.rssIcon}}
{{/texts.summary}} {{#data.hits.hits}}
{{#_source.featured}}
FEATURED
{{/_source.featured}}
{{#_source.showImage}}
{{#_source.image}}
{{/_source.image}}
{{/_source.showImage}}
{{/data.hits.hits}}
{{{_source.title}}} {{#_source.showPrice}} {{{_source.displayPrice}}} {{/_source.showPrice}}
{{#_source.showLink}} {{/_source.showLink}} {{#_source.showDate}}{{{_source.displayDate}}}
{{/_source.showDate}}{{{_source.description}}}
{{#_source.additionalInfo}}{{#_source.additionalFields}} {{#title}} {{{label}}}: {{{title}}} {{/title}} {{/_source.additionalFields}}
{{/_source.additionalInfo}}Anti-RSV F Glycoprotein [11-6-F9]
(Cat#: 151857)
Description
| Cat# | 151857 |
| Applications | ELISA, IF, Fn, WB |
| Antigen/Gene or Protein Targets | Human Respiratory Syncytial (RS) virus Fusion glycoprotein |
| Synonyms | VP70, F0 |
| Reactivity | Human and Virus |
| Relevance | Human Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness and is the chief cause of hospitalization for respiratory tract illness in young children.The glycoprotein F is located on the surface of viral envelope, its function is to induce fusion of viral envelope with host-cell envelope resulting in syncytium formation. The glycoprotein F (also named VP70, F0 or fusion protein) consists of two components: F1 (also named VPG48) and F2 (also named VGP26) held together by disulphide bonds. The reported molecular weight of the VGP26 component varies between 20 to 26 kDa. |
| Host | Mouse |
| Immunogen | Gradient-purified RSF-44 virus (subgroup A) UV inactivated for 20 minutes at 20C |
| Positive Control |
Immunoblot: Ag: gradient-purified RS virus (see figure). Indirect immunofluorescence: staining of RSA-2 infected BSC-1 cells |
| Subclass | IgG1 |
| Myeloma Used | P3X63Ag8.653 |
| Recommended Growing Conditions | Dulbecco’s media containing 20% Fetal Bovine serum (DH20) prepared as follows (for final volume of 300ml: 237ml DMEM plus 60 ml Fetal Bovine Serum plus 3ml L-Glutamine). |
| Strain | Balb/c |
| Notes |
Immunoblot using the reduced and unreduced RS virus shows that 11-6-F9 reacts with the non-reduced form of the virus F protein (VP70). It has a plaque reduction neutralization titer of 10 1.3. Induce in vitro antibody-dependent enhancement of macrophage cells. This antibody has a RS virus 90% plaque neutralization titre of 101.3.and it also has RSV enhancing activity (enhancement index range: 2.5-5.3). Gimenez et al. (1996). Gimenez et al. (1996) was the first report showing that a monoclonal antibody specific for the F protein has enhancing activity. |
| Research Area | Virology |
| References |
Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Europe PMC ID: 8705669 Immunoblot analysis of the human antibody response to respiratory syncytial virus infection. Europe PMC ID: 3572364 Antigenic variation between human respiratory syncytial virus isolates. Europe PMC ID: 3517224 Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates. Europe PMC ID: 6202832 |
Image: The antigen was gradient purified RSN-A2 virus (subgroup A). First antibodies: Lane “Hus”: RSV convalescent human sera; Lane “MAb”: 11-6-F9 antibody. The antigen was analysed by electrophoresis using non-reducing conditions (SDS alone) for Lane “MAb” and reducing conditions for Lane “Hus” as described in Gimenez et al. (1986). The identity and molecular weight of the protein target of this antibody was validated by including within the immunoblot assay (as a marker) a convalescent serum sample from a RS virus infected patient. The protein specificities of the antibodies induced in the human convalescent serum is described in Gimenez et al. (1987).
For Research Use Only.
